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1. introduction 
Although specific membrane-bound receptors for 
morphine have been demonstrated in brain [l-4] , 
the nature of the immediate biochemical events 
which follow the interaction of morphine with these 
receptors remains hypothetical. It has been suggested 
[S] that morphine and some morphine-like drugs can 
reverse the stimulation of cyclic AMP formation 
induced by prostaglandins in rat brain homogenates. 
We have tried to compare the effects in this prepara- 
tion with those obtained in the dopamine-sensitive 
rat caudate homogenate [6]. Dopamine has been 
shown to stimulate modestly the adenylate cyclase 
activity of homogenates from basal ganglia [6], 
superior cervical ganglion [7], corpus striatum 
[8-lo] , cortex [ 111, retina [ 121 and nucleus 
accumbens and olfactory tubercle [13,14]. 
Using various assay conditions, neither prosta- 
glandins (E, and E,) nor morphine altered the 
activity of adenylate cyclase (measured with “P- 
ATP) in brain or caudate homogenates. The nucleotide, 
GTP, which has been shown to play an important 
role in regulating the stimulation of adenylate cyclase 
by several hormones in various tissues [ 1 S-221, 
reproducibly inhibits the basal adenylate cyclase 
activity of caudate nucleus homogenates. The inhibi- 
tory effect of GTP is reversed by dopamine. This effect 
of dopamine is more profound and reproducible than 
is the stimulation of adenylate cyclase by dopamine. 
* Present address: INSERM Rech. Endocr. Enfant., Hopital 
Debrousse, 69322 Lyon, Cedex 1, France. 
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2. Materials and methods 
Brain homogenates from Sprague Dawley male rats 
(120- 150 g) were prepared as described by Collier 
and Roy [5]. Brains were homogenized (seven strokes 
in an Elvehjam-type homogenizer with a teflon pestle) 
in 10 vol (v/w) of cold (4°C) buffer containing 50 mM 
Tris-HCl, pH 7.4, 250 mM sucrose, 1 mM MgClz, 
25 mM KCl, 25 mM NaCl, 0.1 mM EDTA and 1.2 mM 
2-mercaptoethanol. Ten ~1 of the homonate were 
assayed for adenylate cyclase activity in a total volume 
of 0.15 ml of a medium containing 50 mM Tris-HCl. 
pH 7.4,2mM MgCla, 10 mM KCl, 10 mM NaCl, 
0.015% BSA, 3 mM CAMP and 1 FM ATP. Both 
3H-labelled ATP(2.5 X lo6 cpm) [5] and CY-~‘P-ATP 
(5 X IO6 cpm) were used in separate experiments; 
similar data were obtained with these. After incubat- 
ing the samples at 30°C for 5 to 20 min, the reaction 
was stopped by boiling the samples for 2 min. The 
labelled CAMP formed was purified by chromatography 
on alumina columns (23); the results were verified 
by isolation of CAMP by Dowex (50W X 4) 
chromatography followed by a double Ba(OH)a - 
Zn SO4 precipitation [24] . 3 H-Naloxone binding 
studies were performed as previously described [3]. 
For the preparation of caudate nuclei homogenates, 
Sprague Dawley male rats (120- 150 g) were decapitat- 
ed and the caudates were quickly dissected and homo- 
genized (7 strokes in an Elvehjam-type homogenizer 
with a teflon pestle) in 2 mM Tris-maleate, pH 7.4, 
2 mM EGTA (usually 4 caudates in 1.5 ml of the 
hypotonic buffer) at 4°C. Adenylate cyclase activity 
was assayed using 20 ~1 of the homogenate in a final 
volume of 0.1 ml containing 80 mM Tris-maleate, 
North-Holland Publishing Company - Amsterdam 
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pH 7.4, 1.5 mM ATP, 6.0 mM MgS04, 10 mM 
theophylline, and 0.6 mM EGTA (including the EGTA 
added with the homogenate). We did not measure the 
CAMP formed by the method of Gilman [25] but used 
instead labelled ATP ( [(Y-~’ P] ATP, 5 X 1 O6 cpm per 
assay) which was synthesized as described by Symons 
[26,27] and purified (> 95% ATP) by paper 
chromatography (Bennett and Cuatrecasas, unpublished). 
After incubating the samples at 30°C for 2.5 min, the 
reaction was stopped in a boiling water bath for 2 min; 
1 ml of [8-3H] CAMP (30 000 cpm) was added to each 
tube to allow calculations of recovery, and the 32P- 
CAMP formed was purified by chromatography on 
alumina [23]. Over 95% of the 32P-product formed 
was identified as CAMP by DEAE column chromato- 
graphy (Siegel and Cuatrecasas, unpublished). 
3. Results and discussion 
We were unable to demonstrate any activation of 
adenylate cyclase by PGEr or PGE2 (0.1 to 
25 pglrnl), or any effect of morphine (1.5 and 
10 E.cglml), in rat brain homogenates assayed under 
the conditions described by Collier and Roy [5]. Since 
the very low basal activity (0.5-2 pmol/min/mg 
fresh brain) observed under these conditions could be 
explained by the low concentration (1 PM) of ATP 
used, we studied the effects of adding an ATP 
regenerating system (5 mM phosphoenolpyruvate and 
60 &ml of pyruvate kinase) and of increasing the 
concentration of ATP. The ATP regenerating systems 
increased by lo-fold the activity measured with 1 PM 
ATP. Combining 50 I.IM ATP and the ATP regenerat- 
ing system resulted in a 50-fold increase in enzyme 
activity. Even under these conditions, PGEi and/or 
morphine did not affect the activity of brain 
homogenates. The binding of 3 H-naloxone (1 mM) 
was identical to that seen in brain membranes prepared 
by other means [ 1,3] and PGEi had no effect on the 
binding of 3 H-naloxone in either the cyclase assay 
preparation or in normal binding assay homogenates. 
Homogenates of ileum prepared in the same way as 
the brain (except for homogenization, performed with 
a Polytron for 30 set) were responsive to PGEi . Using 
the basic assay conditions (50 PM ATP and regenerat- 
ing system), 10 pg per ml of PGEi stimulated the 
adenylate cyclase activity of the ileum homogenates 
from 22.8 + 0.7 to 33.7 * 0.8 pmol cAMP/min/mg 
fresh tissue. However, no effect of morphine could be 
detected in this system. 
Since under the conditions described above the brain 
homogenate was sensitive to 10 mM NaF (usually two- 
fold stimulation) but not to 10e3 to 10e6 M dopamine, 
we examined the dopamine sensitive caudate prepara- 
tion described by Kebabian and colleagues [6,13] . 
Dopamine usually stimulated the adenylate cyclase 
activity of caudate homogenates with maximal effects 
(50-90% stimulation) occurring with 10d4 M 
dopamine. However, the results were extremely variable, 
reproducibility was poor and dopamine was less 
effective when the homogenate was washed (quickly) 
by suspension in 10 vol of buffer followed by centrifu- 
gation.* 
In attempts to increase the sensitivity of the 
dopamine effect, GTP was examined. GTP always 
inhibited the basal cyclase activity in fresh as well as 
in washed (twice) caudate homogenates. Maximal 
inhibition (30-40%) was obtained with 1 Oe4 M GTP 
(table 1). Dopamine very reproducibly reversed the 
inhibition of adenylate cyclase activity by GTP. 
Maximal reversal (80- 100%) of the inhibition caused 
by 10M4 M GTP was obtained with 10e4 M dopamine 
(table 2). In those experiments where dopamine 
stimulated the basal activity (e.g., by 80%) the inhibi- 
tory effect of 10e4 M GTP was still observed and the 
Table 1 
Effect of GTP on adenylate cyclase activity of 
rat caudate homogenates 
GTP concentration Adenylate cyclase activity* 
0 80.2 * 4.6 
1o-5 M 72.4 f 3.4 
5 X lo-’ M 63.2 f 2.3 
1O-4 M 53.6 * 1.4 
5 X 1O-4 M 54.2 f 1.5 
* pm01 of CAMP per min per mg of fresh caudate, * standard 
error of the mean. 
* The inability of certain studies [28-301 to demonstrate 
dopamine stimulation of adenylate cyclase activity may be 
related to this lack of reproducibility, which here was studied 
with a very sensitive and specific assay which used 3z P-ATP 
as substrate. 
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Table 2 Table 3 
Effect of dopamine on the GTP-inhibited adenylate 
cyclase activity of rat caudate homogenates 
_ 
Effects of GTP, dopamine and isoporterenol on adenylate 
cyclase activity of caudate homogenates and 
liver membranes 
Addition Adenylate cyclase 
activity* 
_ 
GTP 
0 
0 
0 
0 
1O-4 M 
1O-4 M 
1O-4 M 
1o‘4 M 
Dopamine 
0 
1O-6 M 
10.’ M 
1O-4 M 
0 
1O-6 M 
1O-5 M 
1O-4 M 
86.6 + 4.3 
86.7 f 3.9 
96.6 + 5.2 
101.5 * 4.1 
66.6 + 3.2 
65.0 + 3.9 
78.2 f 4.1 
99.6 f 5.4 
Tissue 
CTP 
Adenylate 
Addition cyclase 
-.--- activity 
Dopa- Isopro- 
mine terenol 
* pmol of CAMP per min per mg of fresh caudate, + standard 
error of the mean. 
activity with 10e4 M CTP plus dopamine remained 
slightly lower than that with low4 M dopamine alone. 
Since GTP in the medium could be acting by 
lowering the concentration of free Mg’+ available for 
the adenylate cyclase reaction, we tested the effect of 
varying the concentration of MgS04. Although enzyme 
activity was greater at high (5: 1) compared to low 
(1: 1) MgS04 to ATP ratios, the effect of 10m4 M GTP 
and its reversal by 1 0m4 M dopamine remained the 
same. Varying MgS04 concentrations were also 
examined using various concentrations (0.5 and 2 mM) 
of ATP, and basically the same results were obtained. 
Caudate 
homogenate 0 0 0 74.6 f 3.2 
1O-4 M 0 0 42.3 +_ 2.9 
0 lo-“ M 0 91.2 f 4.1 
1O-4 M 1O-4 M 0 82.3 +_ 3.6 
0 0 1O-6 M 73.0 + 3.5 
1O‘4 M 0 1O-6 M 42.0 f 3.1 
Liver 
membranes 0 0 0 17.6 + 2.3 
1O-4 M 0 0 20.5 f 2.1 
0 10.’ M 0 16.2 i 1.9 
1O-4 M 1O-4 M 0 18.2 * 2.2 
0 0 1O-6 M 17.0? 1.6 
1O-4 M 0 lO-6 M 33.3 ? 2.7 
* pmol of CAMP per min per mg of fresh caudate or of 
membrane protein, * standard error of the mean. 
The effect of dopamine described above appeared to 
be specific for brain tissue. Adenylate cyclase activity 
was measured in caudate homogenates and in liver 
membrane preparations in the same experiment, and 
the effects of isoproterenol and dopamine were studied 
in both systems in the presence and absence of GTP 
(table 3). Isoproterenol ( low6 M) did not affect 
adenylate cyclase activity in caudate homogenates 
whether or not GTP ( 10m4 M) was present. However, 
isoproterenol was effective in liver membranes when 
10T4 M GTP was present. Dopamine, on the other 
hand, did not significantly modify liver adenylate 
cyclase although it was effective on the enzyme from 
the caudate. 
alter adenylate cyclase activity in the presence or 
absence of 10m6 M to 10e4 M GTP and/or 10e4 M 
dopamine. Furthermore, morphine at 1, 5, 10, and 
20 pg per ml, concentrations over 10 000 times the 
dissociation constant of morphine binding [ 11, did not 
modify adenylate cyclase activity in the presence or 
absence of 10m4 M GTP, 10m4 M dopamine, 5 pg/ml 
PGEl and combinations thereof. 
In caudate nucleus homogenates dopamine reverses 
the GTP inhibition of adenylate cyclase activity more 
reproducibly than it stimulates enzyme activity. 
Although it is not yet known whether these two effects 
are related, or which one is physiologically more 
relevant, it is possible that adenylate cyclase activity 
in the caudate may normally be modulated by the 
relative concentrations of GTP and dopamine. 
The prostaglandins, PGEl and PGEz, and morphine 
were tested in the caudate homogenate, which has 
very high levels of opiate binding [2]. At concentra- 
tions of 0.1 to 10 pg/ml, PGEl and PGEz did not 
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